49,364 results match your criteria Multiple Myeloma


Incidence and risk factors for acute kidney injury following autologous stem cell transplantation for multiple myeloma.

Cancer Med 2019 Apr 23. Epub 2019 Apr 23.

Nephrology Department, Fundeni Clinical Institute, Bucharest, Romania.

Acute kidney injury (AKI) is a common complication after allogeneic stem cell transplantation; however, its incidence and outcome in patients transplanted for multiple myeloma (MM) is unknown. We evaluated the incidence, severity, and risk factors for AKI within the first 30 days after autologous stem cell transplantation (ASCT) for MM. We prospectively followed 185 consecutive patients with MM, without chronic renal replacement therapy, who underwent ASCT; 12. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2187DOI Listing

Whole-body MRI of bone marrow: A review.

J Magn Reson Imaging 2019 Apr 23. Epub 2019 Apr 23.

Mater Misericordiae University Hospital, Dublin, Republic of Ireland.

Technical advances in the last two decades have allowed rapid, high-resolution whole-body magnetic resonance imaging (WBMRI). MRI allows unparalleled visualization and detail in the imaging of bone marrow and surrounding soft tissues. The properties of nuclear magnetic resonance allow superb characterization of bone marrow constituents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmri.26759DOI Listing

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.

Nat Commun 2019 Apr 23;10(1):1911. Epub 2019 Apr 23.

Department of Hematology and Medical Oncology, Emory University School of Medicine, 1365 Clifton Rd. NE, Atlanta, GA, 30322, USA.

Multiple myeloma is a malignancy of antibody-secreting plasma cells. Most patients benefit from current therapies, however, 20% of patients relapse or die within two years and are deemed high risk. Here we analyze structural variants from 795 newly-diagnosed patients as part of the CoMMpass study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-019-09555-6DOI Listing

Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activity.

Blood Adv 2019 Apr;3(8):1318-1329

Division of Translational and Regenerative Medicine, Department of Medicine, The University of Arizona Comprehensive Cancer Center, Tucson, AZ.

Inhibition of bromodomain and extra terminal (BET) protein family members, including BRD4, decreases the expression of c-MYC and other key oncogenic factors and also significantly induces histone deacetylase 6 (HDAC6) expression. On the basis of the role of HDAC6 in malignant pathogenesis, we hypothesized that rational cotargeting of HDAC6 and BET family proteins may represent a novel approach that yields synergistic antimyeloma activity. We used genetic and pharmacologic approaches to selectively impair HDAC6 and BET function and evaluated the consequential impact on myeloma pathogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018026484DOI Listing

Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction.

Crit Rev Oncol Hematol 2019 May 27;137:18-26. Epub 2019 Feb 27.

Department of Medicine, Division of Hematology Oncology, Blood and Marrow Transplantation, University of Arizona, Tucson, AZ, 85721, United States; Taussig Cancer Center, Department of Hematology, Medical Oncology, Cleveland Clinic, Cleveland, OH, 44195, United States. Electronic address:

Multiple Myeloma (MM) is primarily a disease of old age with a median age of sixty-nine years at diagnosis. The development of novel therapies for induction and use of autologous stem cell transplantation has resulted in improved clinical outcomes and better quality of life for MM patients. Elderly patients, comprising the majority of MM population, have a higher incidence of age-related comorbidities, frailty and organ dysfunction which complicates the coordination of treatment and limits the selection of therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2019.02.011DOI Listing

Biology and therapy of multiple myeloma.

Med J Aust 2019 Apr 23. Epub 2019 Apr 23.

Royal Prince Alfred Hospital, Sydney, NSW.

Genetic sequencing of the myeloma genome has not revealed a specific disease-determining genetic alteration. Multiple disease subclones exist at diagnosis and vary in clinical importance with time and drug sensitivity. New diagnostic criteria have identified indications for early introduction of therapy. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.5694/mja2.50129
Publisher Site
http://dx.doi.org/10.5694/mja2.50129DOI Listing
April 2019
1 Read

Survival rate of multiple myeloma patients in Indonesia: A retrospective study in multiple myeloma at a single institution.

Ann Med Surg (Lond) 2019 May 2;41:11-15. Epub 2019 Apr 2.

Department of Orthopaedic and Traumatology Cipto Mangunkusumo General Hospital / Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.

Introduction: To evaluate the response and the correlation between survival and prognostic factors in 32 patients with multiple myeloma.

Method: We recruited 32 patients (18 men and 14 women) with mean age 59 years old who were diagnosed with multiple myeloma that were treated with surgery (n = 21) and without surgery (n = 11). 9 patients underwent hemiarthroplasty, 14 patients underwent open reduction and internal fixation and 4 patients underwent spinal decompression and posterior pedicular instrumentation from January 2012 to December 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amsu.2019.03.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460220PMC

Gallbladder Metastases: A Report of Two Cases.

Case Rep Oncol 2019 Jan-Apr;12(1):235-240. Epub 2019 Mar 19.

Virginia Tech Carilion School of Medicine, Division of Gastroenterology and Hepatology, Roanoke, Virginia, USA.

Introduction: Metastasis to the gallbladder is not common and usually manifests an advanced stage of malignancy. Herein, we report a case of triple negative high grade invasive ductal carcinoma of breast with a metastatic lesion to the gallbladder.

Case Presentation: The patient is a 52-year-old female diagnosed with invasive ductal carcinoma treated with mastectomy and chemotherapy. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/497818
Publisher Site
http://dx.doi.org/10.1159/000497818DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465751PMC
March 2019
1 Read

Monoclonal gammopathy of undetermined significance (MGUS).

Blood 2019 Apr 22. Epub 2019 Apr 22.

Medical Oncology/Hematologic Malignancies, Dana-Farber Cancer Institute, United States

Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma cell dyscrasia that consistently precedes multiple myeloma (MM) with a 1% risk of progression per year. Recent advances have improved understanding of the complex genetic and immunologic factors that drive and permit progression from aberrant plasma cell clone to MGUS and overt MM. Additional evidence supports a bidirectional interaction of MGUS cells with surrounding cells in the bone marrow niche that regulates malignant transformation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019846782DOI Listing

Role of urine immunofixation in the complete response assessment of MM patients other than light- chain-only disease.

Blood 2019 Apr 22. Epub 2019 Apr 22.

Hospital Clínic Universitari, IDIBAPS, Barcelona, Spain.

Response criteria for multiple myeloma (MM) require monoclonal protein (M-protein)-negative status on both serum (sIFE) and urine (uIFE) immunofixation-electrophoresis for classification of complete response (CR). However, uIFE is not always performed for sIFE‑negative patients. We analyzed M-protein evaluations from 384 MM patients (excluding those with light-chain-only disease) treated in the GEM2012MENOS65 (NCT01916252) trial in order to determine the uIFE-positive rate in patients who became sIFE-negative post-treatment; and evaluate rates of minimal residual disease (MRD)-negative status and progression-free survival among patients achieving CR, CR but without uIFE available (uncertain CR; uCR), or very good partial response (VGPR). Read More

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood.2019000
Publisher Site
http://dx.doi.org/10.1182/blood.2019000671DOI Listing
April 2019
1 Read

The Effect of Disability on the Diagnosis and Treatment of Multiple Myeloma in Korea: A National Cohort Study.

Cancer Res Treat 2019 Apr 22. Epub 2019 Apr 22.

3Graduate School of Health Science Business Convergence, Chungbuk National University College of Medicine, Cheongju, Korea.

Purpose: This study aimed to determine whether the diagnosis, treatment approach and prognosis of multiple myeloma (MM) vary according to the presence and type of disability.

Materials And Methods: Demographic, socioeconomic, and medical data were obtained from the National Disability Database, the Korean Central Cancer Registry, and the Korean National Health Insurance claims database. An age- and sex-matched cohort was established using a 1:3 ratio constituted with 2,776,450 people with disabilities and 8,329,350 people without disabilities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2018.702DOI Listing

miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma.

Mol Ther Nucleic Acids 2019 Mar 13;16:391-406. Epub 2019 Mar 13.

Department of Precision Medicine, University of Campania "Luigi Vanvitelli," 80138 Naples, Italy; IRGS, Biogem, Molecular and Precision Oncology Laboratory, Via Camporeale, 83031 Ariano Irpino, Italy. Electronic address:

miR-125b, ubiquitously expressed and frequently dysregulated in several tumors, has gained special interest in the field of cancer research, displaying either oncogenic or oncosuppressor potential based on tumor type. We have previously demonstrated its tumor-suppressive role in multiple myeloma (MM), but the analysis of molecular mechanisms needs additional investigation. The purpose of this study was to explore the effects of miR-125b and its chemically modified analogs in modulating cell viability and cancer-associated molecular pathways, also focusing on the functional aspects of stress adaptation (autophagy and senescence), as well as programmed cell death (apoptosis). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.omtn.2019.02.023DOI Listing

Generation of Monoclonal Antibodies Against Natural Products.

J Vis Exp 2019 Apr 6(146). Epub 2019 Apr 6.

Center of Scientific Experiment, Beijing University of Chinese Medicine;

The analysis of the bioactive components present in foods and natural products has become a popular area of study in many fields, including traditional Chinese medicine and food safety/toxicology. Many of the classical analysis techniques require expensive equipment and/or expertise. Notably, enzyme-linked immunosorbent assays (ELISAs) have become an emerging method for the analysis of foods and natural products. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3791/57116DOI Listing

Posterior tibial nerve schwannoma in a multiple myeloma patient: A case report.

SAGE Open Med Case Rep 2019 10;7:2050313X19838441. Epub 2019 Apr 10.

Division of Foot and Ankle, Henry Ford Health System, Detroit, MI, USA.

We report the case of a 61-year-old man with sharp pain, tender mass at the left lower one-third posterior tibial region. The patient has a 10-year history of multiple myeloma and related chemotherapy. A positron emission tomography computed tomography and magnetic resonance imaging indicated the suspect of a posterior tibial nerve tumor. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/2050313X19838441
Publisher Site
http://dx.doi.org/10.1177/2050313X19838441DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458660PMC
April 2019
1 Read

Prognostic significance of upfront radiation therapy in patients with multiple myeloma.

Am J Hematol 2019 Apr 21. Epub 2019 Apr 21.

Department of Medicine, Brown University, Warren Alpert Medical School, Providence, RI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25492DOI Listing

Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.

Mol Ther 2019 Apr 8. Epub 2019 Apr 8.

Allogene Therapeutics, Inc., 210 E. Grand Avenue, South San Francisco, CA 94080, USA. Electronic address:

Clinical success of autologous CD19-directed chimeric antigen receptor T cells (CAR Ts) in acute lymphoblastic leukemia and non-Hodgkin lymphoma suggests that CAR Ts may be a promising therapy for hematological malignancies, including multiple myeloma. However, autologous CAR T therapies have limitations that may impact clinical use, including lengthy vein-to-vein time and manufacturing constraints. Allogeneic CAR T (AlloCAR T) therapies may overcome these innate limitations of autologous CAR T therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ymthe.2019.04.001DOI Listing
April 2019
1 Read

Extramedullary disease in multiple myeloma - controversies and future directions.

Blood Rev 2019 Apr 13. Epub 2019 Apr 13.

Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic. Electronic address:

Extramedullary disease of multiple myeloma (EM) remains a treatment challenge even in the era of new drugs. While many reports analyzing various aspects of EM have been published, mechanism of EM development has not been clarified yet. This review summarizes current knowledge about this clinical entity, including its history, diagnostics, imaging methods, incidence, prognosis, current treatment options, risk factors and known molecular mechanisms that might be involved in pathogenesis of EM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2019.04.002DOI Listing

Clinical features and treatment outcome of elderly multiple myeloma patients with impaired renal function.

J Clin Lab Anal 2019 Apr 19:e22888. Epub 2019 Apr 19.

Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.

Background: Renal impairment (RI) is a most common complication of multiple myeloma (MM), which is associated with an increased risk of early death and worse survival.

Methods: We retrospectively analyzed clinical features and outcomes of 77 MM patients over 70 years old and compared the differences between with and without RI groups.

Results: The percentage of elder MM patients with RI was 61%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcla.22888DOI Listing

A significant incidental finding on cone beam computed tomography: multiple myeloma.

Aust Dent J 2019 Apr 19. Epub 2019 Apr 19.

Private Practice, Perth, Western Australia, Australia.

Cone beam computed tomography is widely used in dentistry. Incidental findings are common, with many requiring intervention or monitoring. We present a rare case of previously undiagnosed, asymptomatic multiple myeloma first identified incidentally on cone beam computed tomography and panoramic radiography. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/adj.12695
Publisher Site
http://dx.doi.org/10.1111/adj.12695DOI Listing
April 2019
3 Reads

Presentation Patterns, Diagnostic Markers, Management Strategies, and Outcomes of IgD Multiple Myeloma: A Systematic Review of Literature.

Cureus 2019 Feb 4;11(2):e4011. Epub 2019 Feb 4.

Internal Medicine, The University of Arizona, Tucson, USA.

Immunoglobulin (Ig) D multiple myeloma (MM) is a rare subtype of MM comprising 2% of all the cases. Malignant plasma cell invasion leads to signs and symptoms similar to other subtypes of MM. The synthesis rate of IgD is lower in IgD MM patients, making it very difficult to diagnose compared to other subtypes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.4011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450588PMC
February 2019

Multiple myeloma immunophenotyping: method validation.

Ann Biol Clin (Paris) 2019 Apr;77(2):197-217

IUC-T laboratoire d'hématologie, CHU de Toulouse, Toulouse, France.

Flow cytometric immunophenotyping has become essential for management of multiple myeloma (assessment of clonality, prognostic information on the risk of progression in gammopathy of undetermined significance, minimal residual disease monitoring). Immunophenotyping of bone marrow plasma cells is routinely used in the haematology laboratory of the University Hospital of Toulouse. To guarantee the reliability of this technique, the laboratory decided to check this method in compliance with the NF ISO EN 15189, standard for medical laboratories requirements. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/abc.2019.1426DOI Listing

[Significance of Neutrophil/Lymphocyte Ratio in the Prognosis of Patients with Multiple Myeloma].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):489-493

Department of Hematology, Gansu Provincial People's Hospital, Lanzhou 730000, Gansu Province, China.

Objective: To study the value of neutrophil/lymphocyte ratio (NLR) in the evaluation of prognosis of patients with multiple myeloma (MM).

Methods: NLR was calculated on the basis of the blood routine examination results of 65 patients with primary MM (MM group) and 83 persons receiving physical examination as control group, and the difference in 2 group was compared; moreover according to the median as threshold, the patients were divided into low NLR group (NLR<2.34) and high NLR group (NLR≥2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.029DOI Listing

[Effect of Bushen Yanggu Decoction on Multidrug Resistance of Multiple Myeloma Cell Line KM3/BTZ].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):482-488

Department of Orthopedics The Third Affiliated Hospital of Guangzhou University of Tranditional Chinese Medicine;Guangzhou 510000, Guangdong Province, China, E-mail:

Objective: To explore the effect of Bushen Yanggu Decoction (BYD) on drug resistance and proliferation of human multiple myeloma-resistant KM3/BTZ cells.

Methods: Human multidrug-resistant KM3/BTZ cells were established by Bortezomib (BTZ) gradient induction. The effects of commonly used chemotherapeutic drugs and serum containing Bushen Yanggu Decoction (BYD) on the proliferation of KM3 cells and KM3/BTZ cells were detected by MTT assay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.028DOI Listing

[Effect of siRNA-Interfering β-Catenin Expression on MDR of Human Multiple Myeloma Cell Line].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):477-481

Department of Orthopedics, The Third Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510000, Guangdong Province, China,E-mail:

Objective: To investigate the effecr of siRNA-interfering β-catenin expression on drug-resistance of multiple myeloma cells.

Methods: The multiple myeloma cell line RPMI-8226 was cultured in vitro. The maphalan-resistant cell model was established by concentration gradient ascending of durg, then the drug-resistant cell line was instantaneously transfected with β-catenin siRNA, the sensitivity of RPMI 8226 cells to maphalan was detected by CCK-8 meltod before and after the transfection with siRNA; the mRNA and protein expression of β-catenin was detected by qRT-PCR and Western blot respectively, the apoptosis of cells was detected by flow cytometry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.027DOI Listing
April 2019
1 Read

[Significance of Detecting Serum Complement C3 and C4 in Patients with Multiple Myeloma].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):472-476

Department of Hematology, Chaohu Hospital Affiliated to Anhui Medical University,Chaohu 238000, Anhui Province, China.

Objective: To investigate the significance of detecting serum complement C3 and C4 in patients with multiple myeloma (MM) and to explore its correlation with myeloma bone disease (MBD).

Methods: The levels of serum complement C3 and C4 in 69 MM patients and 30 healthy people were examined by scatter nephelometry. The bone density of L1-4 vertebral body, bilateral femoral neck and bilateral hip joints were measured by dual energy bone density meter (DXA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.026DOI Listing

[Curcumin Increases the Chemosensitivity of Multiple Myeloma to Bortezomib by Inhibiting the Notch1 Signaling Pathway].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):464-471

Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China,E-mail:

Objective: To evaluated the effect of curcumin on the bortezomib-resistant myeloma cells and the expression of Notch1 signaling pathway, in order to further explore its potential mechanism.

Methods: Curcumin, bortezomib, and curcumin combined bortezomib were added into RPMI 8266, U266, 5 nmol/L bortezomib-resistant RPMI 8266 (RPMI 8226-V5R), 5 nmol/L bortezomib-resistant U 266 (U266-V5R) and CD138+ plasma cells respectively. The cell proliferation was measured by MTT assay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.025DOI Listing

[Effects of Oridonin on Proliferation Apoptosis of Human Multiple Myeloma Cells H929 in Vitro].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Apr;27(2):458-463

Department of Hematology, Affiliated Hospital, Nanjing University of Traditional Chinese Medicine, Nanjing 210029, Jiangsu Province, China,E-mail:

Objective: To investigate the effects of oridonin (ORI) on the proliferation and apoptosis of human multiple myeloma cell line H929 and its possible mechanism.

Methods: H929 cells were exposed to ORI 0、4、8、12、16、20、24、28、32 μmol/L for 12, 24 and 36 hours respectively. The prolifcration inhibitory effect of ORI on H929 cells was determined by MTT assay and then the working concentrations of ORI were determined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2019.02.024DOI Listing
April 2019
1 Read

Acute non-heparin-induced thrombocytopenia during hemodiafiltration in a patient with multiple myeloma.

Clin Case Rep 2019 Apr 22;7(4):699-702. Epub 2019 Feb 22.

Department of Clinical Laboratory Kyoto University Hospital Kyoto Japan.

This report demonstrates that not only heparin-induced thrombocytopenia, but also hemodialysis conditions (platelet activation due to hemodiafiltration and heparin underdosing) may markedly reduce the platelet count and cause clotting in the hemodialysis circuit in patients in a hypercoagulable state. The clot prevention effects of bortezomib are therefore of great importance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.1997DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452500PMC

Oligosecretory Primary Plasma Cell Leukemia with Atypical Morphological Abnormality.

Intern Med 2019 Apr 17. Epub 2019 Apr 17.

Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Japan.

Plasma cell leukemia (PCL) is a rare variant of multiple myeloma. The detection of plasma cells in the peripheral blood and monoclonal protein in the serum or urine is important for the diagnosis of PCL. However, it is sometimes difficult to diagnose PCL in patients with atypical plasma cell morphology and/or those without detectable monoclonal protein. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.2472-18DOI Listing

Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later.

Drugs R D 2019 Apr 16. Epub 2019 Apr 16.

Department of Hematology, Medical University of Lodz, Ul. Ciolkowskiego 2, 93-510, Lodz, Poland.

Bortezomib is a dipeptidyl boronic acid that selectively inhibits the ubiquitin proteasome pathway, which plays a role in the degradation of many intracellular proteins. It is the first-in-class selective and reversible inhibitor of the 26S proteasome, with antiproliferative and antitumor activity. It exerts its anti-neoplastic action mainly via the inhibition of the nuclear factor-κB pathway components associated with cell proliferation, apoptosis, and angiogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40268-019-0269-9DOI Listing

Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients.

Leukemia 2019 Apr 16. Epub 2019 Apr 16.

Myeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital-Monash University, Melbourne, VIC, Australia.

Monitoring tumour burden and therapeutic response through analyses of circulating cell-free tumour DNA (ctDNA) and extracellular RNA (exRNA) in multiple myeloma (MM) patients were performed in a Phase Ib trial of 24 relapsed/refractory patients receiving oral azacitidine in combination with lenalidomide and dexamethasone. Mutational characterisation of paired BM and PL samples at study entry identified that patients with a higher number of mutations or a higher mutational fractional abundance in PL had significantly shorter overall survival (OS) (p = 0.005 and p = 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0469-xDOI Listing

NMR Methods for Quantitative Isotopomer Rates in Real-Time Metabolism of Cells.

Chembiochem 2019 Apr 16. Epub 2019 Apr 16.

University of Birmingham, HWB-NMR, CR UK Institute of Cancer Studies, Vincent Drive, Edgbaston, B15 2TT, Birmingham, UNITED KINGDOM.

Tracer-based metabolism is becoming increasingly important to study metabolic mechanisms in cells. NMR offers several approaches to measure label incorporation in metabolites, including 13C and 1H-detected spectra. The latter are generally more sensitive but quantification depends on the proton carbon 1JCH coupling constant which varies significantly between different metabolites. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/cbic.2019000
Publisher Site
http://dx.doi.org/10.1002/cbic.201900084DOI Listing
April 2019
2 Reads

Successful hematopoietic stem-cell mobilization with plerixafor plus granulocyte-colony stimulating factor in multiple myeloma patients treated with pomalidomide.

Int J Hematol 2019 Apr 13. Epub 2019 Apr 13.

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.

Autologous stem-cell transplantation is an effective procedure for the treatment of multiple myeloma, and involves the collection of hematopoietic stem cells (HSCs). However, in some patients, HSCs in the bone marrow fail to mobilize. Pomalidomide upregulates CXCR4 in hematopoietic stem cells, in a manner similar to that of lenalidomide, and is, thus, likely to have a negative impact on hematopoietic stem-cell mobilization in multiple myeloma patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02622-0DOI Listing
April 2019
1 Read

Effects of triptolide on bone marrow-derived mesenchymal stem cells from patients with multiple myeloma.

Exp Ther Med 2019 May 12;17(5):3291-3298. Epub 2019 Mar 12.

Department of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310012, P.R. China.

Triptolide (TPL), an extract of the Chinese herb Hook F, is a potent anti-inflammatory agent that further possesses anticancer activity. Its antiproliferative effects are well established. Only few studies have focused on TPL as a potential treatment in multiple myeloma (MM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2019.7373DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447813PMC
May 2019
1 Read

Clinical Outcomes in Multiple Myeloma Post-Autologous Transplantation-A Single Centre Experience.

Indian J Hematol Blood Transfus 2019 Apr 21;35(2):215-222. Epub 2018 Jul 21.

Department of Haematology, Christian Medical College, Vellore, 632004 India.

There is paucity of data from developing countries on the clinical outcomes in myeloma post-autologous transplantation. In this retrospective study, we used hospital records to retrieve data of patients with multiple myeloma undergoing autologous stem cell transplantation (ASCT) from January 1995 to December 2014 at our centre. During the study period, 245 patients underwent ASCT for myeloma. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12288-018-0989-y
Publisher Site
http://dx.doi.org/10.1007/s12288-018-0989-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438994PMC
April 2019
5 Reads

Stem Cell Transplantation in Multiple Myeloma: Very Much Alive and Kicking.

Indian J Hematol Blood Transfus 2019 Apr 13;35(2):205-207. Epub 2019 Mar 13.

2Department of Internal Medicine, PGIMER, Chandigarh, 160012 India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12288-019-01111-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438993PMC
April 2019
2 Reads

Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells.

Leukemia 2019 Apr 15. Epub 2019 Apr 15.

Division of Hematology, Mayo Clinic, Rochester, MN, 55905, USA.

IL-6 signaling plays a crucial role in the pathogenesis of a number of diseases, including multiple myeloma, primary amyloidosis, cytokine release syndrome and other inflammatory conditions. It is central for the growth and survival of malignant plasma cells. IL-6R and IL-6ST receptors transduce IL-6 signaling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0470-4DOI Listing
April 2019
1 Read

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.

Proc Natl Acad Sci U S A 2019 Apr 15. Epub 2019 Apr 15.

State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, China;

Relapsed and refractory (R/R) multiple myeloma (MM) patients have very poor prognosis. Chimeric antigen receptor modified T (CAR T) cells is an emerging approach in treating hematopoietic malignancies. Here we conducted the clinical trial of a biepitope-targeting CAR T against B cell maturation antigen (BCMA) (LCAR-B38M) in 17 R/R MM cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1819745116DOI Listing
April 2019
2 Reads

When Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma Rounds.

Clin Lymphoma Myeloma Leuk 2019 Mar 8. Epub 2019 Mar 8.

Division of Hematology, Oncology and Stem Cell Transplant, Rush University Medical Center, Chicago, IL. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.02.008DOI Listing
March 2019
1 Read

Clinicopathological spectrum of renal parenchymal involvement in B-cell lymphoproliferative disorders.

Kidney Int 2019 Mar 15. Epub 2019 Mar 15.

Department of Nephrology and Renal Transplantation, Centre Hospitalier Universitaire, Université de Poitiers, Poitiers, France; CNRS UMR 7276, INSERM UMR 1262, Université de Limoges, Limoges, France; INSERM CIC 1402, Centre Hospitalier Universitaire, Poitiers, France.

The clinicopathological characteristics of kidney infiltration in B-cell lymphoproliferative disorders remain poorly described. We retrospectively studied 52 adults with biopsy-proven malignant B-cell kidney infiltration, including Waldenström's macroglobulinemia (n=21), chronic lymphocytic leukemia (n=11), diffuse large B-cell lymphoma (DLBCL) (n=8), other lymphoma (n=11), and multiple myeloma (n=1). Kidney disease varied according to the underlying lymphoproliferative disorder. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.kint.2019.01.027DOI Listing
March 2019
1 Read

HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action.

Cancers (Basel) 2019 Apr 4;11(4). Epub 2019 Apr 4.

Department of Hematology/Oncology, Research Hospital, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.

HDACs are critical regulators of gene expression that function through histone modification. Non-histone proteins and histones are targeted by these proteins and the inhibition of HDACs results in various biological effects. Moreover, the aberrant expression and function of these proteins is thought to be related to the pathogenesis of multiple myeloma (MM) and several inhibitors have been introduced or clinically tested. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11040475DOI Listing
April 2019
1 Read

The role of long non-coding RNAs in multiple myeloma.

Eur J Haematol 2019 Apr 15. Epub 2019 Apr 15.

Henan Institute of Haematology, Department of Hematology, Henan Cancer Hospital, The Affliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.

Multiple myeloma(MM) is still an incurable disease and its pathogenesis involves cytogenetics and epigenetics. In recent years, the roles of long non-coding RNAs (lncRNAs) in MM have been deeply studied by scholars. LncRNAs are defined as a class of nonprotein-coding transcripts greater than 200 nucleotides in length, which are involved in a large spectrum of biological processes, including proliferation, differentiation, apoptosis, invasion and chromatin remodeling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13237DOI Listing
April 2019
1 Read

Is there still a role for stem cell transplantation in multiple myeloma?

Cancer 2019 Apr 15. Epub 2019 Apr 15.

Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.

High-dose chemotherapy and autologous stem cell transplantation (ASCT) are a standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (MM). The introduction of novel agents, which range from immunomodulatory drugs and proteasome inhibitors to monoclonal antibodies and have now been integrated into both induction and salvage regimens, has dramatically revolutionized the treatment landscape of MM and challenged the role of high-dose chemotherapy and ASCT in treating MM. These advances have led to a number of provocative questions. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.32060
Publisher Site
http://dx.doi.org/10.1002/cncr.32060DOI Listing
April 2019
2 Reads